Viewing Study NCT01222039



Ignite Creation Date: 2024-05-05 @ 10:57 PM
Last Modification Date: 2024-10-26 @ 10:26 AM
Study NCT ID: NCT01222039
Status: COMPLETED
Last Update Posted: 2016-11-18
First Post: 2010-10-14

Brief Title: Multicenter Clinical Trial for the Evaluation of Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease
Sponsor: Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
Organization: Andalusian Network for Design and Translation of Advanced Therapies

Study Overview

Official Title: Multicenter Clinical Trial Phase III Randomized Controlled for the Evaluation of Safety and Feasibility of Therapy With Two Different Doses of Allogenic Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease
Status: COMPLETED
Status Verified Date: 2016-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: CMMEICH2008
Brief Summary: The main purpose of this trial is to assess the safety and feasibility of treatment with two-dose infusion of allogeneic mesenchymal stem cells from adipose tissue expanded in vitro in patients undergoing haematopoietic stem cell transplantation HSCT who have developed chronic and extensive graft versus host disease GVHD

Mesenchymal stem cells MSCs express low levels of HLA class I molecules and do not express class II molecules neither CD40 CD80 and CD86 being unable to induce proliferation of allogeneic lymphocytes In addition MSCs inhibit lymphocyte proliferation by inhibiting cell division and maintaining these cells in a quiescent state This supports the hypothesis that MSCs are universal suppressors
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None